MARLBOROUGH, Mass.–(DWPR)–Hologic, Inc. (Nasdaq: HOLX) announced a collaboration with the Centers for Disease Control and Prevention (CDC) to develop analyte specific reagents (ASRs) for detecting H5N1 bird flu. The ASRs, integral to laboratory-developed tests (LDTs), aim to enhance preparedness for potential escalations in the current H5N1 outbreak, which has impacted birds and humans globally.
“During the COVID-19 pandemic, our teams rapidly developed critical tests to combat the virus,” said Jennifer Schneiders, Ph.D., President, Diagnostic Solutions at Hologic. “Our proven expertise in assay development positions us uniquely to proactively address evolving public health threats.”
Hologic’s ASRs will be developed on the Panther Fusion® system, an automated molecular testing platform. With over 1,700 Panther® systems in U.S. laboratories—nearly 500 of which are Panther Fusion systems—the technology offers scalability and high throughput, processing over 1,000 results in 24 hours. The platform’s Open Access® functionality allows labs to automate their own LDTs, seamlessly integrating with FDA-approved workflows.
The ASR initiative builds on Hologic’s robust diagnostic portfolio, including the Panther Fusion® SARS-CoV-2 assay and the Aptima® SARS-CoV-2 assay, which were pivotal during the COVID-19 pandemic. With over 68 million tests shipped to 40 countries in 2020, Hologic continues to innovate, including FDA clearance in 2023 for a multi-target assay detecting SARS-CoV-2, influenza A and B, and RSV from a single sample.
For more information, visit www.hologic.com.
About Hologic, Inc.
Hologic, Inc. is a global leader in women’s health, dedicated to advancing medical technologies for detection, diagnosis, and treatment of health conditions. The company aims to raise global healthcare standards through innovation. To learn more, visit www.hologic.com or connect on LinkedIn, Facebook, X (Twitter), Instagram, and YouTube.
Forward-Looking Statements
This release contains forward-looking statements subject to risks and uncertainties, including product efficacy and commercial success. Hologic disclaims any obligation to update forward-looking statements to reflect future developments.
Contacts
Media Contact
Bridget Perry
Sr. Director, Corporate Communications
(+1) 508.263.8654
[email protected]
Investor Contact
Ryan Simon
Vice President, Investor Relations
(+1) 858.410.8514
[email protected]